Novartis Buys Tourmaline Bio: A Billion-Dollar Heart Deal
Markets & Money Today | 2 Min News | The Daily News Now! - A podcast by The Daily News Now! - Miercuri
Categories:
Novartis drops $1.4 billion to snag Tourmaline Bio, betting big on a potential heart disease breakthrough! The deal centers on pacibekitug, a promising anti-inflammatory drug targeting atherosclerotic cardiovascular disease. Tourmaline's stock skyrockets, while Novartis gains a potential blockbuster. Is this the future of heart disease treatment? Hosted on Acast. See acast.com/privacy for more information.
